LEO Pharma Receives Scientific Approval of Enstilar® for the Treatment of Psoriasis in EU
Ballerup, Denmark (ots/PRNewswire) - The marketing approval of Enstilar® would make it the first fixed combination topical foam treatment for people living with psoriasis vulgaris in the EU. LEO Pharma today announced that it received scientific approval of Enstilar® (calcipotriol/betamethasone dipropionate 50 micrograms/g / 0,5 mg/g) for the treatment of psoriasis ...